{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:10:17Z","timestamp":1756282217035,"version":"3.44.0"},"reference-count":17,"publisher":"BMJ","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>About 1 in 100 people has bipolar disorder (manic depression) at some point in their lives.1 Associated mood swings of depression and mania can be both unpleasant and destructive.2 It is advised to start medical treatment early, and traditionally this has involved the use of mood stabilisers, antipsychotics and antidepressants.2 \u25bcAsenapine (Sycrest \u2013 Lundbeck) is a new sublingual antipsychotic drug, licensed for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.3 Here we review the evidence and practical implications associated with the use of this new medication.<\/jats:p>","DOI":"10.1136\/dtb.2012.06.0112","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T09:22:48Z","timestamp":1339665768000},"page":"69-72","source":"Crossref","is-referenced-by-count":0,"title":["\u25bcAsenapine for bipolar I disorder?"],"prefix":"10.1136","volume":"50","member":"239","published-online":{"date-parts":[[2012,6,14]]},"reference":[{"key":"2025082700321324000_50.6.69.1","unstructured":"Royal College of Psychiatrists, 2010. Bipolar disorder [online]. Available: http:\/\/www.rcpsych.ac.uk\/mentalhealthinfo\/problems\/bipolardisorder\/bipolardisorder.aspx [Accessed 24 May 2012]."},{"key":"2025082700321324000_50.6.69.2","unstructured":"Royal College of Psychiatrists, 2010. Medications for mania [online]. Available: http:\/\/www.rcpsych.ac.uk\/mentalhealthinfo\/problems\/bipolardisorder\/medicationsformania.aspx [Accessed 24 May 2012]."},{"key":"2025082700321324000_50.6.69.3","unstructured":"Sycrest 5mg and 10mg sublingual tablets. Summary of product characteristics, UK. Lundbeck Limited, September 2010."},{"key":"2025082700321324000_50.6.69.4","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition (DSM-IV). Washington DC: American Psychiatric Association, 2000."},{"key":"2025082700321324000_50.6.69.5","unstructured":"Joint Formulary Committee. British National Formulary. Edition 62. London: BMJ Group and RPS Publishing, September 2011."},{"key":"2025082700321324000_50.6.69.6","unstructured":"National Institute for Health and Clinical Excellence, 2006. Bipolar disorder. Clinical guideline 38 [online]. Available: http:\/\/publications.nice.org.uk\/bipolar-disorder-cg38 [Accessed 24 May 2012]."},{"key":"2025082700321324000_50.6.69.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00748.x"},{"key":"2025082700321324000_50.6.69.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.12.028"},{"key":"2025082700321324000_50.6.69.9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"2025082700321324000_50.6.69.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00749.x"},{"key":"2025082700321324000_50.6.69.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.04.005"},{"key":"2025082700321324000_50.6.69.12","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31823f872f"},{"key":"2025082700321324000_50.6.69.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60873-8"},{"key":"2025082700321324000_50.6.69.14","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.192"},{"key":"2025082700321324000_50.6.69.15","unstructured":"European Medicines Agency, 2010. Sycrest [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/001177\/WC500096896.pdf [Accessed 24 May 2012]."},{"key":"2025082700321324000_50.6.69.16","unstructured":"Scottish Medicines Consortium, 2012. Asenapine 5mg, 10mg sublingual tablet (Sycrest) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/files\/advice\/asenapine_Sycrest_FINAL_February_2012_for_website_amended_080312.pdf [Accessed 24 May 2012]."},{"key":"2025082700321324000_50.6.69.17","unstructured":"All Wales Medicine Strategy Group, 2010. Asenapine (Sycrest) [online]. Available: http:\/\/www.wales.nhs.uk\/sites3\/Documents\/371\/asenapine%20%28Sycrest%29%20SOA%20post%20pricing%20change.pdf [Accessed 24 May 2012]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2012.06.0112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:32:23Z","timestamp":1756279943000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2012.06.0112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,14]]},"published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1136\/dtb.2012.06.0112"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2012.06.0112","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}